The Peptide Research Guide

At its most fundamental level, a peptide is a short chain of amino acids linked together by a specific type of chemical bond called a peptide bond. That's it. Two amino acids joined together form a dipeptide. Three form a tripeptide. Somewhere around 50 amino acids, the chain becomes long enough to be called a protein.

The human body uses 20 standard amino acids — think of them as 20 letters in a chemical alphabet. The number of unique sequences (and therefore unique peptides) those 20 letters can produce is effectively limitless. A chain of just 10 amino acids has over 10 trillion possible unique arrangements. This is why peptide research spans endocrinology, neuroscience, oncology, metabolic medicine, dermatology, and regenerative biology simultaneously.

Peptides vs. Proteins — Where's the Line?

The distinction is more convention than hard science. Generally:

Note that insulin sits right at the border — it's technically classified as a protein, but it's small enough that researchers synthesize it the same way as other peptides, and it's often discussed in peptide research literature.

Why Peptides Are Biologically Powerful

Your body already uses peptides as its primary chemical messaging system. Hormones like insulin, glucagon, and oxytocin are peptides. Pain-modulating endorphins are peptides. The signal that tells your pituitary gland to release growth hormone is a peptide. Even the signal that starts the process of tissue repair after an injury is mediated by peptide signaling cascades.

This is exactly why synthetic peptide research has attracted so much scientific attention — researchers aren't introducing something foreign to biology. They're studying and working with the same molecular language the body already speaks.

Frederick Sanger Sequences Insulin (1953)

British biochemist Frederick Sanger accomplishes something that had seemed almost impossibly complex: he determines the exact sequence of every amino acid in insulin — all 51 of them. This is the first time any protein or peptide has had its complete structure mapped. The work takes 12 years and earns Sanger the Nobel Prize in Chemistry in 1958.

Why does this matter? Because knowing the exact sequence means you know the exact blueprint. It proved that peptides have a precise, reproducible chemical structure — and planted the idea that if you know the sequence, you can eventually build it yourself.

Vincent du Vigneaud Synthesizes the First Peptide Hormone (1953)

The same year Sanger completes his insulin sequencing work, American biochemist Vincent du Vigneaud does something even more dramatic: he synthesizes oxytocin — a 9 amino acid peptide — entirely from scratch in the laboratory. This is the first time any hormone has ever been artificially created. Du Vigneaud receives the Nobel Prize in Chemistry in 1955. The era of synthetic peptide research has officially begun.

Robert Merrifield Invents Solid-Phase Peptide Synthesis (1963)

This is the single most important technical development in peptide research history. Before 1963, synthesizing even a short peptide required months of painstaking chemistry in solution — protecting groups, purification steps, and yields that degraded with every additional amino acid added. It was slow, expensive, and limited to short chains.

American chemist Robert Bruce Merrifield changed everything with a deceptively simple idea: anchor the first amino acid to a solid resin bead, then add each subsequent amino acid one at a time in a controlled reaction. Wash away the unreacted chemicals. Repeat. When the sequence is complete, cleave the finished peptide from the bead.

The Endorphin Discovery (1975)

In 1975, Scottish researchers John Hughes and Hans Kosterlitz identify enkephalins — two 5 amino acid peptides produced naturally in the brain that bind to the same receptors as morphine. Shortly after, a larger family of these endogenous opioid peptides — called endorphins — is characterized. The discovery that the brain produces its own pain-modulating peptides triggers an explosion of neuropeptide research throughout the late 1970s and 1980s and fundamentally changes neuroscience.

GHRH Isolated: The Growth Hormone Axis Unlocked (1982)

For decades, researchers knew that the hypothalamus controlled pituitary growth hormone release — but the exact signal remained elusive. In 1982, Roger Guillemin's lab at the Salk Institute finally isolated and sequenced Growth Hormone Releasing Hormone (GHRH) — a 44 amino acid peptide produced in the hypothalamus that triggers the pituitary to secrete GH.

This discovery opened the door to a class of synthetic GHRH analogs — peptides engineered to mimic this signal. Tesamorelin, studied for its effects on GH and IGF-1 levels in metabolic research models, is a direct product of this research lineage: a stabilized GHRH analog designed to have a longer half-life than the natural peptide.

BPC-157: From Gastric Protein to Research Compound (1991–2000s)

In the early 1990s, Croatian pharmacologist Predrag Sikirić and his team at the University of Zagreb began investigating a protein isolated from human gastric juice — the body's own stomach acid environment. Within this protein, they identified a stable 15 amino acid fragment that appeared to have unusual properties in preclinical models.

They named it Body Protection Compound 157 (BPC-157). The gastric environment is one of the most chemically hostile in the body — yet certain peptide fragments survive it intact. Sikirić's team published a series of studies throughout the 1990s and 2000s documenting BPC-157's observed behavior in angiogenesis (new blood vessel formation), gastrointestinal tissue, and tendon-to-bone healing models.

The Gila Monster and GLP-1 (1992)

Glucagon-like peptide-1 (GLP-1) was characterized from proglucagon gene sequencing in the early 1980s and found to play a role in insulin secretion and glucose regulation. But it had a fatal flaw for therapeutic research: it degrades in the bloodstream within 2 minutes.

In 1992, endocrinologist John Eng discovered something remarkable while studying the Gila monster lizard's venom gland: a peptide called exendin-4 that bound to the same GLP-1 receptor in humans, but with a half-life measured in hours, not minutes. The lizard only eats a few times a year — it had evolved a slow-degrading version of the peptide signal.

This single discovery launched the GLP-1 receptor agonist research field. The structural analysis of exendin-4 became a template for engineering longer-acting GLP-1 analogs. The field has since expanded to dual and triple-receptor agonists — compounds that simultaneously target GLP-1, GIP, and glucagon receptors, such as Retatrutide (GLP-3RT), which is studied for its effects on metabolic signaling across all three axes.

Triple-Receptor Agonism: The Next Frontier

For years, GLP-1 receptor agonists dominated metabolic research. Then dual-agonists — compounds targeting both GLP-1 and GIP receptors — demonstrated that hitting two pathways produced additive effects. Researchers at Eli Lilly and independent labs began asking: what happens if you target three?

Retatrutide, also known as GLP-3RT in research settings, is a triple-receptor agonist studied for simultaneous activity at GLP-1, GIP, and glucagon receptors. The glucagon component is particularly interesting — glucagon typically raises blood glucose (the opposite of GLP-1), but in the context of triple-agonism, the glucagon receptor component appears to drive increased energy expenditure. This is an active area of research, with Phase 3 clinical trials ongoing as of 2024.

Collagen Peptides and Multi-Blend Research

Collagen is the most abundant protein in the human body — roughly 30% of total protein mass — built from repeating tripeptide sequences dominated by glycine, proline, and hydroxyproline. The study of collagen-derived peptide signaling in fibroblasts has attracted significant research interest for its role in cellular repair and extracellular matrix maintenance.

Multi-peptide research compounds like GLOW are studied in the context of cellular repair signaling and collagen synthesis pathways, combining compounds with complementary mechanisms in a single lyophilized formulation.

GLU-600 and Glucose Regulation Research

Beyond the GLP receptor axis, researchers are investigating peptides that interact directly with glucose transporter signaling and insulin receptor sensitivity. GLU-600 is studied as a metabolic peptide for its observed effects in glucose regulation and insulin signaling research models — a different mechanistic approach than GLP receptor agonism, targeting downstream signaling pathways in metabolic regulation.